Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLihong ShouHuzhou Central HospitalJJJie JinBeijing Institute of TechnologyHJHuifang JiangMinistry of Education

Discussion

Loading...

Member takes

Implication

Phase III trial shows that etoposide plus pegfilgrastim improves mobilization efficiency and safety compared to cyclophosphamide plus G-CSF in multiple myeloma.

Key Points

  • Eighty-three point seven percent of patients in the EAP regimen reached the ideal collection threshold after one apheresis session.
  • The median cumulative output of CD34+ cells was significantly higher in the EAP arm at 13.2 ×10⁶/kg, compared to 5.5 ×10⁶/kg for CG (p＜0.0001).
  • Randomized comparison assessed mobilization efficacy using etoposide, pegfilgrastim, and cyclophosphamide in adults with newly diagnosed multiple myeloma.
  • EAP regimen's efficacy suggests a viable first-line treatment option for resource-limited settings needing self-sufficiency.

Cite This Study

Shou et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db9dhttps://doi.org/10.1182/blood-2025-5960
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Research Article: Cyclophosphamıde–Etoposıde + G-csf Compared to G-csf alone in Perıpheral Blood Stem Cell Mobılızatıon for Multıple Myeloma2022
  2. 2Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial2025
  3. 3Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma2025
  4. 4Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy2025
  5. 5Intermediate-High-Dose Cyclophosphamide for Stem Cell Mobilization in Lymphoma: A Single-Center Retrospective Study2025